GLP1.tools

Ibutamoren: The Complete 2026 Guide (Mechanism, Dosing, Cost)

Quick Answer

Bottom line first: Ibutamoren is a growth hormone secretagogue. Increased GH and IGF-1 levels.

Ibutamoren at a glance:

  • Drug class: Growth hormone secretagogue
  • Route: subcutaneous injection (peptides) or oral (small molecules)
  • Typical frequency: once daily to once weekly depending on agent
  • Half-life: varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677)

If you're trying to figure out whether Ibutamoren is right for you — or for someone you care about — the right starting point is the basic biology. Ibutamoren is a growth hormone secretagogue. Increased GH and IGF-1 levels.

What is Ibutamoren?

Growth hormone secretagogues stimulate endogenous GH release through either the GHRH receptor (GHRH analogs) or the GHS-R1a/ghrelin receptor (ghrelin mimetics).

There is no single FDA-licensed manufacturer of Ibutamoren for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. Ibutamoren is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class growth hormone secretagogue works by targeting specific receptor pathways. Here's what to expect.

How Ibutamoren Works in the Body

Growth hormone secretagogues stimulate endogenous GH release through either the GHRH receptor (GHRH analogs) or the GHS-R1a/ghrelin receptor (ghrelin mimetics). The receptor target — compound-specific — drives the downstream effects users care about: increased gh and igf-1 levels.

The pharmacokinetics matter for daily use. Ibutamoren has a half-life of varies (minutes for sermorelin; days for CJC-1295 DAC; hours for MK-677), which determines how often it is dosed. The standard route of administration is subcutaneous injection (peptides) or oral (small molecules), and the typical schedule is once daily to once weekly depending on agent.

For more detail on the underlying biology, see our breakdown of how Ibutamoren works.

Who Uses Ibutamoren?

Ibutamoren is most relevant for people whose situation maps to its approved indications: specific approved members include sermorelin (historically, pediatric GHD) and tesamorelin (HIV-lipodystrophy); most others are research-only.

People who should avoid Ibutamoren include those with the following:

  • allergy to the active ingredient or any excipient
  • pregnancy or breastfeeding (per label)
  • conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of Ibutamoren include:

  • injection-site reactions
  • fluid retention
  • joint pain
  • headache

Serious risks — uncommon but worth knowing — include:

  • impaired glucose tolerance
  • carpal tunnel syndrome
  • theoretical IGF-1-mediated effects on tumor growth

We have a more detailed breakdown in our Ibutamoren side-effects guide.

Ibutamoren vs Alternatives

Recombinant human growth hormone remains the standard for diagnosed GH deficiency. If you are weighing Ibutamoren against another option, our comparison pages include Ibutamoren Side Effects Decoded: What's Normal vs. What Isn't, What Results Should You Expect from Ibutamoren? A Practical Guide, The Real Ibutamoren Price Tag in 2026 — With and Without Insurance.

Bottom Line

Ibutamoren delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Phase 2 and 3 data show meaningful benefit, with phase 3 confirmation pending in some cases. If you are considering Ibutamoren, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Frequently Asked Questions

Sources

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.

Last updated: 2026-04-29 · For informational purposes only. Consult a healthcare provider.